The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
A £2 price would be ( helpful), £5 a game-changer ( i.e. an option to retire early!) It's impossible to predict where this will peak or at what level but between £2-5 based on a premium to the NAV of the current holdings and future staking rewards. Perhaps within 12-18 months.
The company has a strong value proposition for the NHS and hence commissioner approval with budgets absorbing that spend unless the baseline for Integrated Commisioning Boards can be adjusted for the 2425 financial year to allow for the adoption of this innovative test. Buys are 3x Sell orders yet the bid price is almost 5% down! Perhaps a large buyer is being accomodated by market makers at a favourable entry level. DYOR. I used to commission services within the NHS, IMO- buy and hold . There is bound to be volatility in the price, after all this is AIM, where fortunes can be made and lost too.
I agree, a very impactful interview with the CEO. The commercial proof of concept is important within the NHS supported by a health economic impact. I work within the NHS and will reach out to the CEO ( as I used to commission specialist cancer services). I have started with a small ( 1% of my investment portfolio) position. The share price will drift without more news flow.
More manipulation today. The net buys exceeded the sells by >10m shares against a 12% decline. If sells exceeded buys against such a daily price fall then that would signal a temporary change in collective investor sentiment. The same thing happened with Argo Blockchain on the way to its meteoritic price rise. If you believe the methodology they have developed then hold otherwise find a boring share with modest returns at best. But- do use trailing stops on the way up and set sales at price targets you're comfortable with . Good luck and forget the trolls and shorters.
I agree, the retracement is due to day traders.
The net accumulation is evident all the way down to the low of today. IMO- a " tree shake" very common with AIM- listed stocks and perpetrated by market makers who widen the bid- offer spread to scare weak holders if the shares.
IMO, there is accumulation taking place around key levels of price support. I added another (494,437 shares at 2.0225p: below the mid price of the (bid-offer) therefore that trade is showing as a £10k sell whereas its a buy. I added again 493,827 at 2.025p that trade is showing as ( unknown); whereas its another buy. The traders are not thinking of the long- term potential of what QBT could mean to improvements in bitcoin mining efficiency. Volatile price action but with significant upside potential. DYOR!
The overall portfolio of investments made looks promising and tge IC article is balanced and well- articulated IMO. My initial modest buy at 60.92p is showing as a ( sell) as it was kindly executed by my broker below the mid point of the ( bid- offer). A long- term hold I hope.
The recent Investors Chronicle article suggests this investment trust is unlikely to reduce its dividend. Science laboratories as tenants and drug development companies are hardly going to dissappear any time soon.
I wish to ask fellow investors why there was a spike in buys 9 days ago and the gap- up in price? I see this as a resilient income play and more resilient owner of speciality real estate
Previous pessimism regarding future deal flow for Physiomics floored the bid price which gapped down a few weeks back and I got stopped out from a 1% Co. holding. I've been on the sidelines watching the positive divergence in net accumulation within the narrow price range prior to the recent break out.
There are not a large volume of chunky trades coming through yet but it would appear that private investor awareness is steadily improving.
The technology has significant potential IMO. I'll see if my modest limit order works out tommorow.
IMHO, although the progress is as expected the market had marked down the share price due to perceived risk of requiring additional funding that involves share dilution. OCTP could simply take on debt finance.
The output of the phase 1 study by the end of September is what I think will move the share price meaningfully upwards again.
I agree in that I have lost faith in our IC small-cap analyst: stocks are ( often) suggested as buys often when the technical indicators show prices declining against the moving averages and/ or with evident distribution. RBGP is oversold but now faces resistance.
The stock has seen net accumulation over the last 7 weeks with some significant volume spikes indicating ( IMHO), the inflow of some well- informed investors. I am content to initiate an initial position below the price at which the CFO purchased >£22k of shares in 23rd June. I'll accumulate up to a £10k position with a trailing stop loss. Enabling the development of Precision Medicine is an important theme linked to the increased personalisation of oncology treatments. I have an Oncology background and work in the NHS , so I can claim to have some insights in this niche area. Diaceutics is " under the radar" of most investors. Let's hope that the old adage of : " from small acorns grow great oak trees" applies here over time!